Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 10:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lubricant Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

Lidocaine for Pessary Check Pain Reduction

NCT05493735
View directory record Official record
Conditions
Pelvic Organ Prolapse, Stress Urinary Incontinence
Interventions
Lidocaine Hcl 2% Jelly, Placebo Jelly
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 18, 2026, 10:35 PM EDT
Not listed Phase 2 Interventional

Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy

NCT03813056
View directory record Official record
Conditions
Fuchs Endothelial Dystrophy
Interventions
Glanatec, Optive, Ophthalmic Solution, Descemet Membrane Endothelial Keratoplasty
Drug · Procedure
Lead sponsor
Michael D. Straiko, MD
Other
Eligibility
30 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Dry Eye Treatments on the Ocular Surface

NCT01797822
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Dry Eye Syndrome
Interventions
Dexamethasone, Artificial tear
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms

NCT01007253
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
PL nasal spray, fluticasone furoate (FF), PL eye drops, olopatadine (OLO)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Not applicable Interventional Results available

Comparison of Orbital Versus Rotational Atherectomy Effects On Coronary Microcirculation in PCI

NCT03021577
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
Orbital Atherectomy System (OAS), Rotablator Rotational Atherectomy System, Magnetic Resonance Imaging (MRI)
Device · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants

NCT05878067
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
ABBV-444
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Azusa, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Not applicable Interventional

Lidocaine Lubricant in Pediatric Urethral Catheterization

NCT00596375
View directory record Official record
Conditions
Fevers, Pain
Interventions
Lubricant Instillation, Lidocaine Lubricant
Procedure · Drug
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
2 Months to 2 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 16, 2008 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution

NCT05938699
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
NCX 470, Placebo
Drug
Lead sponsor
Nicox Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Artificial Tears, Tear Lipids and Tear Film Dynamics

NCT05705518
View directory record Official record
Conditions
Dry Eye
Interventions
Systane Complete PF, Refresh Relieva PF, Refresh Optive Mega-3 PF, CVS Health Lubricant Eye Drop (PG 0.6%)
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

NCT01732757
View directory record Official record
Conditions
Conjunctivitis, Allergic
Interventions
Alcaftadine 0.25%, Olopatadine 0.2%, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
Drug
Lead sponsor
Allergan
Industry
Eligibility
10 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer

NCT01346371
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Refresh Tears 0.5% Lubricant Eye Drops, Bepreve 1.5% Ophthalmic Solution
Drug
Lead sponsor
Minnesota Eye Consultants, P.A.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 18, 2026, 10:35 PM EDT
Withdrawn Not applicable Interventional

Sphenopalatine Ganglion Block for Postdural Puncture Headache in the Emergency Department

NCT02517931
View directory record Official record
Conditions
Postdural Puncture Headache
Interventions
Sphenopalatine Ganglion Block, Placebo
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Functionality of Male Condoms With a Silicone Elastomer Vaginal RIng

NCT01755741
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Placebo Vaginal Ring, Condom
Combination Product · Device
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Berkeley, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Multicenter, Open-Label, Non-Comparative Study of the Safety and Contraceptive Efficacy of the Woman's Condom

NCT01223313
View directory record Official record
Conditions
Contraception
Interventions
Woman's Condom
Device
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
511 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
10
States / cities
Los Angeles, California • Baltimore, Maryland • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 18, 2026, 10:35 PM EDT
Withdrawn Phase 4 Interventional

A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®

NCT02028312
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Loteprednol etabonate, Artificial Tears, Restasis
Drug
Lead sponsor
Edward Holland, MD
Other
Eligibility
21 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Edgewood, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Not applicable Interventional Results available

Evaluation of SYSTANE Ultra Lubricant Eye Drops

NCT00702377
View directory record Official record
Conditions
Dry Eye
Interventions
SYSTANE Ultra, Optive
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis

NCT01533480
View directory record Official record
Conditions
Keratoconjunctivitis Due to Adenovirus, Viral Shedding
Interventions
Zirgan, genteal gel
Drug
Lead sponsor
Lifelong Vision Foundation
Other
Eligibility
14 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cool vs Room-temperature Artificial Tears

NCT05832996
View directory record Official record
Conditions
Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis), Central Retinal Vein Occlusion With Macular Edema, Exudative Age-Related Macular Degeneration, Unspecified Eye, Cystoid Macular Edema, Ocular Surface Disease, Dry Eye Sensation, Eye Pain
Interventions
Refresh Plus Preservative-free Lubricant Eye Drops
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 105 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 18, 2026, 10:35 PM EDT
Terminated Phase 4 Interventional Results available

The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye

NCT00553735
View directory record Official record
Conditions
Dry Eye
Interventions
Cyclosporine A 0.05%, Arificial Tear
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Ketorolac 0.4% in Prostaglandin Suppression

NCT00791323
View directory record Official record
Conditions
Inflammation
Interventions
Ketorolac 0.4%, Lubricating Eye Drop
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2011 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Results available

Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®

NCT01170884
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution, bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Results available

Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy

NCT02121847
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
cyclosporine 0.05% ophthalmic emulsion, carboxymethylcellulose-based lubricant eye drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 18, 2026, 10:35 PM EDT
Completed Not applicable Interventional

Evaluation of the Tolerability and Efficacy of CWT-f-002 Lubricant Eye Drops

NCT05660681
View directory record Official record
Conditions
Dry Eye Disease
Interventions
glycerin 0.7%/PEG 400 0.3%, polyethylene glycol 400 0.4%/propylene glycol 0.3%
Drug
Lead sponsor
Calm Water Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 18, 2026, 10:35 PM EDT
Terminated Phase 2 Interventional Results available

Celecoxib for Thyroid Eye Disease

NCT02845336
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Celecoxib, artificial tears
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 18, 2026, 10:35 PM EDT